ClinicalTrials.gg
CompletedNCT00747110Updated Jun 26, 2012

Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)

A Phase 3 interventional study of budesonide and mesalazine in Colitis, Ulcerative, sponsored by Dr. Falk Pharma GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-06-26.

Sponsored by Dr. Falk Pharma GmbH · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
343
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing budesonide in Colitis, Ulcerative — 1 open to participants now, 1 under way, none of them phase 3. Budesonide · Colitis, Ulcerative.

Enrollment
2nd of 10
343 · median 183
Started
2007
the only one that year
Phase 3
6 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
2 of 10
Dr. Falk Pharma GmbH

Among the 10 studies testing budesonide in Colitis, Ulcerative, this one is the 2nd largest by enrollment, is the only one that started in 2007, is one of 6 in phase 3, and was the 1st registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

1 of the 10 studies testing budesonide in Colitis, Ulcerative is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing budesonide in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to prove the therapeutic equivalence and safety of once-daily 9 mg budesonide versus 3 g mesalazine in a 8-week treatment in patients with active ulcerative colitis.

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

Keywords

  • 5-ASA
  • mesalamine
  • mesalazine
  • budesonide
  • ulcerative colitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed ,
  2. Men or women aged 18 to 75 years,
  3. Active ulcerative colitis, except proctitis limited to 15 cm ab ano, confirmed by endoscopy and histology,
  4. Established disease (presence of blood or mucus in the stools) or new diagnosis (bloody stools occurring at least during 14 days prior to baseline visit),
  5. Clinical Activity Index (CAI) >= 6 and Endoscopical Index (EI) >= 4,
  6. Women of , if heterosexually active, have to apply a highly effective method of , which is defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptive method, some intrauterine devices (IUDs), sexual abstinence, or vasectomised partner. The investigator is responsible for determining whether the subject has adequate birth control for study participation.

Exclusion criteria

Exclusion Criteria:

  1. Crohn's disease, indeterminate colitis, ischaemic colitis, radiation colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis),
  2. Toxic megacolon,
  3. Baseline stool positive for germs causing bowel disease,
  4. Diarrhoea as a result of the presence of other symptomatic organic disease(s) of the gastrointestinal tract,
  5. Active peptic ulcer disease,
  6. Haemorrhagic diathesis,
  7. Asthma, diabetes mellitus, infection, osteoporosis, glaucoma, cataract, or cardiovascular disease if careful medical monitoring is not ensured,
  8. Severe co-morbidity substantially reducing ,
  9. Active colorectal cancer or a history of colorectal cancer,
  10. Active other than colorectal cancer or treatment with anticancer drugs during the last 5 years. Patients with a history of cancer other than colorectal cancer and at least five years of uneventful follow up and no signs of recurrence may be eligible,
  11. within 3 months and/or (oral, intravenous [IV] or topical rectal) within 4 weeks prior to baseline,
  12. Current relapse occurred under maintenance treatment with > 2.4 g mesalazine per day,
  13. Abnormal renal function (Serum Cystatin C > [ULN]),
  14. Abnormal hepatic function (, AST or AP >= 2 x ULN) or liver cirrhosis,
  15. Known intolerance//resistance to study drugs or drugs of similar chemical structure or pharmacological profile, or to any of the other constituents of the study drugs,
  16. Doubt about the patient's cooperation, e.g., because of addiction to alcohol or drugs,
  17. Existing or intended pregnancy or breast-feeding,
  18. Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
343 participants (actual)

Study arms

  • Experimental
    A

    9mg budesonide OD

    Drug: budesonide

  • Active comparator
    B

    3g mesalazine OD

    Drug: mesalazine

Interventions

  • 3x 3mg budesonide capsules once daily

    Also known as: Budenofalk 3mg capsules

  • 3x 1000mg mesalazine onc daily

    Also known as: Salofalk 1000mg granules

06

What researchers measure

Primary outcomes

  1. Rate of clinical remission (defined by CAI <= 4, with stool frequency and rectal bleeding subscores of ´0´) at week 8 (LOCF)

    Time frame: week 8 (LOCF)

Secondary outcomes

  1. Time to first resolution of clinical symptoms

    Time frame: within 8 weeks

  2. CAI in the course of the study

    Time frame: week 0, 2, 4, 6, 8

  3. Disease Activity Index (DAI)in the course of the study

    Time frame: week 0 and 8 (LOCF)

  4. Endoscopical Index (EI)in the course of the study

    Time frame: week 0 and 8 (LOCF)

07

Study locations

1 site
  • Klinikum St. Marien
    Amberg, 92224, Germany
08

References and documents

Publications

  • Gross V, Bunganic I, Belousova EA, Mikhailova TL, Kupcinskas L, Kiudelis G, Tulassay Z, Gabalec L, Dorofeyev AE, Derova J, Dilger K, Greinwald R, Mueller R; International BUC-57 Study Group. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. J Crohns Colitis. 2011 Apr;5(2):129-38. doi: 10.1016/j.crohns.2010.11.006. Epub 2010 Dec 14. PubMed 21453882 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Aug 2008 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2008
First posted
Sep 4, 2008
Start
Oct 2007
Primary completionActual
Aug 2008
CompletionActual
Aug 2010
Last update
Jun 26, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00747110
Responsible party
Sponsor
First posted
Sep 4, 2008
Start date
Oct 2007
Primary completion
Aug 2008
Completion
Aug 2010
Last update
Jun 26, 2012

Study contacts

Ralph Mueller, Dr
study director · Dr. Falk Pharma GmbH

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion